secwatch.observer — SEC 8-K summary
======================================

Issuer:     VIVOS INC (RDGL)
CIK:        0001449349
Form:       8-K
Filed at:   2022-01-27T23:59:59+00:00
Accession:  0001493152-22-002410
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos 2021 recap: first equine IsoPet therapy, FDA pre-sub for RadioGel IDE, production improved 3x
--------------------------------------------------------------------------------

- University of Missouri performed first equine IsoPet therapy; excellent outcome confirmed after monitoring.
- Pre-submission meeting with FDA for RadioGel IDE; used rapid breakthrough review; revised IDE to be submitted after biocompatibility tests.
- Polymer production time reduced and output increased by factor of three; contaminants reduced below FDA guidelines.
- New provisional patent filed covering improved hydrogel, other isotopes, and anti-circumvention techniques.
- Capital structure in excellent shape: no toxic debt or derivatives; all SEC filings timely.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1449349/000149315222002410/0001493152-22-002410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1449349/000149315222002410/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-002410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer